HomeInsightsStock Comparison

Astrazeneca Pharma India Ltd vs Sandu Pharmaceuticals Ltd Stock Comparison

Astrazeneca Pharma India Ltd vs Sandu Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jun 21, 2025

Key Highlights

  • The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8883 as of 20 Jun 15:30.
  • The P/E Ratio of Astrazeneca Pharma India Ltd is 0 as of March 2023 .The P/E Ratio of Sandu Pharmaceuticals Ltd is 33.3 as of March 2023.
  • The Market Cap of Astrazeneca Pharma India Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Sandu Pharmaceuticals Ltd is ₹ 50.43 crore as of March 2023.
  • The revenue of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sandu Pharmaceuticals Ltd for the Mar '25 is ₹ 14.14 crore as compare to the Dec '24 revenue of ₹ 18.4 crore. This represent the decline of -23.15%.
  • The ebitda of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sandu Pharmaceuticals Ltd for the Mar '25 is ₹ 0.52 crore as compare to the Dec '24 ebitda of ₹ 1.02 crore. This represent the decline of -49.02%.
  • The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Sandu Pharmaceuticals Ltd changed from ₹ 0.11 crore to ₹ 0.33 crore over 8 quarters. This represents a CAGR of 73.21% .
  • The Dividend Payout of Astrazeneca Pharma India Ltd changed from 3.46 % on March 2020 to 37.15 % on March 2024 . This represents a CAGR of 60.76% over 5 yearsThe Dividend Payout of Sandu Pharmaceuticals Ltd changed from 36.33 % on March 2021 to 52.93 % on March 2024 . This represents a CAGR of 9.86% over 4 years.

Share Price

* All values are in Rupees

PE

Market Cap

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Astrazeneca Pharma India Ltd

  • AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
  • The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
  • The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
  • Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Sandu Pharmaceuticals Ltd

  • Sandu Pharmaceuticals Ltd (SPL) was established in 1985.
  • The Company is mainly engaged in the business of manufacturing and trading of Ayurvedic medicines under the brand name SANDU. SPL came out with a public issue of 17.70 lac equity shares at par, aggregating Rs 1.77 cr, in Sep.'94, to part-finance its new project in Goa costing Rs 7.28 cr to manufacture ayurvedic medicines and formulations.
  • This plant employs the latest material handling systems and other modern machinery and has the most hygienic production facilities to attain the highest possible quality standards.
  • Ayurvedic products have a very good market in India and abroad due to their minimal side effects. The company commenced commercial production of Ayurvedic Medicines & Formulations, at the Goa plant in 1996-97.
  • Thereafter, it commenced production of manufacturing Unit II in Goa from May, 2002.

Astrazeneca Pharma India Ltd News Hub

News

Astrazeneca Pharma India Ltd leads losers in 'A' group

Orient Cement Ltd, India Cements Ltd, Concord Biotech Ltd and ERIS Lifesciences Ltd are am...

Read more

20 Jun 2025 15:00

News

AstraZeneca Pharma slides as MD Sanjeev Panchal steps down; Praveen Rao Akkinepally to take charge

Panchal is set to transition to a global role within the AstraZeneca Group, based in Gaith...

Read more

10 Jun 2025 09:49

News

Astrazeneca Pharma India Ltd Spurts 7.28%

Astrazeneca Pharma India Ltd gained 7.28% today to trade at Rs 8545.4. The BSE Healthcare ...

Read more

02 Jun 2025 09:30

News

AstraZeneca Pharma soars after Q4 PAT jumps 48% YoY

Profit before tax (PBT) stood at Rs 78.47 crore in Q4 FY25, up 44.35% year-on-year, and up...

Read more

02 Jun 2025 10:10

News

Volumes soar at Astrazeneca Pharma India Ltd counter

Max Healthcare Institute Ltd, Godrej Consumer Products Ltd, Mphasis Ltd, Indraprastha Gas ...

Read more

02 Jun 2025 11:00

News

Astrazeneca Pharma India Ltd leads gainers in 'A' group

Sun Pharma Advanced Research Company Ltd, Bank of Maharashtra, Reliance Power Ltd and Genu...

Read more

02 Jun 2025 12:00

Sandu Pharmaceuticals Ltd News Hub

News

Board of Sandu Pharmaceuticals recommends final dividend

Sandu Pharmaceuticals announced that the Board of Directors of the Company at its meeting ...

Read more

29 May 2025 10:50

News

Sandu Pharmaceuticals to table results

Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

19 May 2025 10:56

News

Sandu Pharmaceuticals to convene board meeting

Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 F...

Read more

05 Feb 2025 12:52

News

Sandu Pharmaceuticals declare Quarterly Result

Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 N...

Read more

05 Nov 2024 13:43

News

Board of Sandu Pharmaceuticals recommends final dividend

Sandu Pharmaceuticals announced that the Board of Directors of the Company at its meeting ...

Read more

13 Aug 2024 09:53

News

Sandu Pharmaceuticals AGM scheduled

Sandu Pharmaceuticals announced that the 39th Annual General Meeting (AGM) of the company ...

Read more

13 Aug 2024 09:53

BlinkX Score for Sandu Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Astrazeneca Pharma India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Astrazeneca Pharma India Ltd and Sandu Pharmaceuticals Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Sandu Pharmaceuticals Ltd?

Market cap of Astrazeneca Pharma India Ltd is 22,207 Cr while Market cap of Sandu Pharmaceuticals Ltd is 48 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Sandu Pharmaceuticals Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Sandu Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Sandu Pharmaceuticals Ltd?

As of June 21, 2025, the Astrazeneca Pharma India Ltd stock price is INR ₹8883.0. On the other hand, Sandu Pharmaceuticals Ltd stock price is INR ₹50.5.

How do dividend payouts of Astrazeneca Pharma India Ltd and Sandu Pharmaceuticals Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Sandu Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions